Vantage Biosciences has dosed the first patient in a Phase 2 clinical trial of VX-01, potentially the first oral treatment for non-proliferative diabetic retinopathy (NPDR).
Researchers at The Lundquist Institute have developed VX-01, a humanized monoclonal antibody that effectively targets the CotH protein on fungal cells causing mucormycosis, a deadly infection with mortality rates approaching 60%.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.